Get the Stockscreener App
1.44
1.41%
0.02
Geron Corp stock is traded at $1.44, with a volume of 4.78M.
It is up +1.41% in the last 24 hours and up +17.07% over the past month.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
See More
Previous Close:
$1.42
Open:
$1.41
24h Volume:
4.78M
Relative Volume:
0.35
Market Cap:
$923.79M
Revenue:
$196.12M
Net Income/Loss:
$-69.59M
P/E Ratio:
-13.81
EPS:
-0.1043
Net Cash Flow:
$-126.13M
1W Performance:
-4.00%
1M Performance:
+17.07%
6M Performance:
+9.92%
1Y Performance:
+11.63%
1-Day Range:
$1.4001
$1.49
1-Week Range:
$1.35
$1.51
52-Week Range:
$1.04
$2.01
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.44 | 910.96M | 196.12M | -69.59M | -126.13M | -0.1043 |
VRTX
Vertex Pharmaceuticals Inc
|
485.65 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.69 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
860.55 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
186.16 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
267.47 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Why Did GERN Stock Tumble 10% Pre-Market Today? - Stocktwits
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Geron's New Business Chief Gets Option on 1.7M Shares - Stock Titan
Geron Corporation Grants Inducement Stock Options to New HiresEstimate Accuracy - dars.gov.et
Geron (GERN) Grants Inducement Stock Options to New Employees - Yahoo Finance
Geron appoints Chinmaya Rath as chief business officer - Investing.com
Veteran dealmaker from Novartis and Cellworks joins Geron to steer RYTELO growth - Stock Titan
ETFs Investing in Geron Corporation Stocks - TradingView
Geron stock leans on its myelofibrosis story - ad-hoc-news.de
GERN News | GERON CORP (NASDAQ:GERN) - ChartMill
Form 4 Geron Corporation For: 1 July By Investing.com - Investing.com Canada
Geron (GERN) director Robert J. Spiegel receives 6,103-share stock grant for board fees - Stock Titan
Geron Corporation (GERN) Shows Modest Bounce as Key Support HoldsOBV Breakout - dars.gov.et
GERN Forecast — Price Target — Prediction for 2027 - TradingView
Geron (GERN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
GERON CORP (GERN) Stock Chart - ChartMill
GERN Stock Steadies As Geron Builds Commercial Momentum - StocksToTrade
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Geron Corp (GERN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Geron Corp (GERN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Geron Corp (GERN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Geron dangles 690,000 options to recruit eight new employees - Stock Titan
Geron Corp (GERN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Geron Corp (GERN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Geron Corp (GERN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Geron Corp (GERN) Institutional Confidence - TradingKey
Geron Corp (GERN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GERN Stock Builds Momentum On Strong RYTELO Data - StocksToTrade
GERN Stock Steadies As Real‑World RYTELO Data Fuel Bullish Buzz - timothysykes.com
Geron Corp stock (US3741631036): Phase 3 data keeps focus on first commercial launch - Ad-hoc-news.de
GERN: RYTELO’s expanding use and strong clinical data drive steady growth and future pipeline potential - TradingView
Earnings call transcript: Geron Q1 2026 shows revenue growth, stock rises - Investing.com
Geron Corp stock (US3741631036): Focus on valuation as short interest eases - AD HOC NEWS
After Plunging 26.6% in 4 Weeks, Here's Why the Trend Might Reverse for Geron (GERN) - Yahoo Finance
GERN SEC FilingsGeron Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - Yahoo Finance
1GERN.MI Technical Analysis | Trend, Signals & Chart Patterns | GERON CORP (BIT:1GERN) - ChartMill
Geron Shareholders Expand Equity Plan and Elect Directors - The Globe and Mail
Geron (NASDAQ: GERN) adds 4.5M shares to 2018 equity incentive plan - Stock Titan
Geron (NASDAQ: GERN) director awarded 220,000 options at $1.26 strike - Stock Titan
Geron (NASDAQ: GERN) director awarded stock options for 220,000 shares at $1.26 - Stock Titan
Geron (GERN) awards director Susan Molineaux 220,000 stock options - Stock Titan
Geron (GERN) director granted 220,000 stock options at $1.26 - Stock Titan
Geron (GERN) director Dawn Carter Bir awarded 220,000 stock options - Stock Titan
GERNGeron Corp Stock Price and Quote - Finviz
Geron Corporation Q1 2026 Earnings: Narrower-Than-Expected Loss as Rytelo Commercialization AdvancesDividend Growth Analysis - Bölüm Sonu Canavarı
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
GERN: All proposals passed; clinical and commercial strategies advancing, with key trial data ahead - TradingView
Geron Corporation’s SWOT analysis: biotech stock faces sales headwinds - Investing.com
Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo! Finance Canada
Geron Corp stock (US3741631036): new stock option grants keep hiring momentum in focus - AD HOC NEWS
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):